Top in cardiology: FDA OKs second pulsed field ablation system; BP drug reduces anxiety
Click Here to Manage Email Alerts
The FDA approved a second pulsed field ablation system for the treatment of paroxysmal atrial fibrillation based on real-world data from the MANIFEST-17K registry and positive findings from the pivotal ADVENT clinical trial.
“Tissue preferentiality and long-term efficacy, combined with markedly shorter procedure times and learning curves, position the Farapulse PFA System with strong potential to become a practice-changing technology for both U.S. physicians and patients alike,” Vivek Y. Reddy, MD, director of cardiac arrhythmia services for The Mount Sinai Hospital and The Mount Sinai Health System, said in a press release from Boston Scientific, the manufacturer.
It was the top story in cardiology last week.
In another top story, children and young adults with autism spectrum disorder experienced reduced symptoms of anxiety after 12 weeks of treatment with the common BP medication propranolol.
Researchers did not, however, observe any association between propranolol treatment and improvements in social interaction and language.
Read these and more top stories in cardiology below:
FDA approves second pulsed field ablation system to treat atrial fibrillation
The FDA approved a second pulsed field ablation system for the treatment of adults with drug-refractory, recurrent, symptomatic, paroxysmal atrial fibrillation. Read more.
BP medication may reduce anxiety symptoms in children, young adults with autism
Children and young adults with autism spectrum disorder experienced reduced anxiety symptoms after 12 weeks of treatment with the BP medication propranolol vs. placebo, although it did not improve scores for social interaction and language. Read more.
Healthy lifestyle paired with statins may boost life expectancy
The combination of statin use and healthy lifestyle was linked to a 30% lower risk for all-cause death and 44% reduced risk for cardiovascular death in people at high cardiovascular risk vs. those not taking statins with an unhealthy lifestyle, data show. Read more.
Navigating menopausal hormone therapy as CVD risk grows requires ‘nuanced approach’
For women experiencing disruptive, bothersome hot flashes, the use of menopausal hormone therapy — a one-time standard but later feared treatment option — is far from straightforward. Read more.
Universal risk prediction model may better estimate CVD for primary, secondary prevention
Researchers reported that a universal risk prediction model incorporating traditional risk factors and cardiac biomarkers accurately estimated risk for adults both with and without baseline atherosclerotic CVD. Read more.